Treating cancer from the inside out®
Game-changing therapies at the forefront of innovation in radiopharmaceutical cancer therapy
About
Perspective Therapeutics is on a mission to transform cancer treatment with targeted alpha particle therapy
Perspective Therapeutics is a radiopharmaceutical company dedicated to developing image-guided, targeted alpha-particle therapies (TATs) for the treatment of cancer.
Technology
Our radioisotope technology delivers radiation at a cellular level
Our revolutionary Pb-212-based alpha-particle radiotherapies are designed to deliver powerful alpha radiation directly to cancer cells utilizing high-affinity targeting peptides.
In contrast to conventional radiotherapy, this approach targets more potent alpha particles directly to tumor cells, delivering significantly higher energy at a shorter range. Due to its short half-life, the rapid decay of Pb-212 leads to potentially greater tumor cell killing while avoiding the emergence of resistance and limiting the damage to healthy tissue.
In addition, our image-guided theranostics platform allows physicians to confirm tumor target expression and off-target distribution prior to treatment to assist with patient selection and optimize outcomes.
Perspective Therapeutics uses proprietary targeting peptides conjugated to radioisotopes via a proprietary Pb-specific chelator to image tumors, and then deliver alpha-particle radiopharmaceuticals to attack them on a cellular level.
Therapy
Therapeutic Areas
Pipeline
Oncology pipeline of image-guided alpha-particle radiotherapies
Most programs leverage the chemically matched isotope pair Pb-203/212 conjugated to high-affinity, tumor-specific peptides for image-guided alpha particle cancer therapies.
| PROGRAM (TARGET) |
TARGET DISEASE | CANDIDATE EVALUATION | HUMAN CLINICAL IMAGING | PHASE 1/2 | REGISTRATION ENABLING STUDY | STATUS |
|---|---|---|---|---|---|---|
| VMT01/02 (MC1R) |
Melanoma (MC1R Imaging & Therapy) |
|
Next cohort is open for enrollment
Enrolling |
|||
| VMT-α-NET (SSTR2) |
Neuroendocrine Tumors Other SSTR2 Expressing Tumors |
|
Cohort 2: Enrolling Cohort 3: Pending FDA alignment Under evaluation |
|||
| PSV359 (FAP-α) |
Multiple Solid Tumors | Cohort 1: Enrolling | ||||
| PSV4XX (PSMA) | Prostate (PSMA Imaging & Therapy) |
Under evaluation | ||||
| Undisclosed Program 5 | Multiple Solid Tumors | Under evaluation | ||||
| Undisclosed Program 6 | Multiple Solid Tumors | Under evaluation | ||||
| Undisclosed Program 7 | Multiple Solid Tumors | Under evaluation | ||||
| Pre-Targeting Platform | Multiple Solid Tumors | Under evaluation | ||||
News
Read the latest news from Perspective Therapeutics
May 30, 2025Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the 2025 ASCO Annual Meeting
Updated interim results with an additional ~16 weeks of follow-up on nine patients in Cohort 1 (2.5 mCi) and Cohort 2 (5.0 mCi) and initial safety findings in an additional 33 patients treated in Cohort 2 from the ongoing Phase 1/2a study were presented[212Pb]VMT-α-NET continued to have a favo...
May 12, 2025Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2025 Results
First of several clinical updates through mid-2026 accepted for presentation at the 2025 American Society of Clinical Oncology Annual Meeting, with recruitment progressing for all three of our clinical stage potential new medicines based on our next generation targeted radiopharmaceutical technology...
